Drug Profile
Adjuvanted influenza virus vaccine inactivated trivalent - Vaxine
Alternative Names: Adjuvanted seasonal 2008 trivalent inactivated influenza vaccine - VaxineLatest Information Update: 06 Feb 2023
Price :
$50
*
At a glance
- Originator Vaxine
- Class Influenza virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Influenza virus infections
Most Recent Events
- 06 Feb 2023 Phase-I/II development is ongoing Australia (Vaxine pipeline, February 2023)
- 27 Sep 2017 No recent reports on development identified - Phase-I/II for Influenza virus infections (Prevention) in Australia (IM)
- 16 Sep 2015 Vaxine completes a phase I/II trial for Influenza virus infections (Prevention, In elderly subjects and patients with chronic diseases) in Australia (ACTRN12608000364370)